"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
An unnecessary FDA policy is making it nearly impossible for schizophrenics without stable medical care to get clozapine, the ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Weeks after that announcement, BMS announced a $14 billion deal to buy Karuna Therapeutics, whose M1- and M4-targeting schizophrenia drug was already under FDA review. The September approval of ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
Zacks.com on MSN5h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline SetbackThe third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback